Appili Therapeutics Inc.
APLIF
$0.01
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.50K | -- | -8.80K | 77.40K | 3.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.50K | -- | -8.80K | 77.40K | 3.40K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 75.50K | -- | -8.80K | 77.40K | 3.40K |
| SG&A Expenses | 413.70K | 464.40K | 692.00K | 321.20K | 479.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.02M | 1.16M | 1.76M | 1.55M | 1.99M |
| Operating Income | -942.90K | -1.16M | -1.77M | -1.47M | -1.98M |
| Income Before Tax | -692.70K | -880.90K | 178.20K | -381.70K | -544.30K |
| Income Tax Expenses | 25.40K | 22.30K | 19.30K | -7.10K | 900.00 |
| Earnings from Continuing Operations | -718.10K | -903.20K | 158.90K | -374.60K | -545.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -718.10K | -903.20K | 158.90K | -374.60K | -545.10K |
| EBIT | -942.90K | -1.16M | -1.77M | -1.47M | -1.98M |
| EBITDA | -940.50K | -1.16M | -1.76M | -1.47M | -1.98M |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.27M | 121.27M |
| Average Diluted Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.27M | 121.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |